It has been demonstrated that the beneficial effects of GLP-1 and GLP-1 agonists on the cardiovascular system do not rely on lowering blood glucose levels, but rather on improving endothelial dysfunction and left ventricular dysfunction. Here, GLP1R is linked to endothelial dysfunction.